UCLA's Priscilla Hsue Wins a $6.3 Million NIH Grant for the Olympic-HIV Trial of an Oral GLP-1 Drug
UCLA cardiologist Dr. Priscilla Hsue received a $6.3 million R01 grant from the National Heart, Lung, and Blood Institute to lead Olympic-HIV, a multicenter, randomized, placebo-controlled trial of an oral GLP-1 drug in adults aged 40 and older with HIV and at least one cardiovascular risk factor, UCLA Health announced on November 18. Over 52 weeks, the trial will use imaging and blood tests to measure arterial inflammation, coronary plaque, immune activation, and other markers. People with HIV have higher rates of heart disease, driven in part by chronic inflammation. The release does not name the drug or the planned enrollment.